{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:17:53Z","timestamp":1790713073270,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH","award":["R01-AI078881\u2018"],"award-info":[{"award-number":["R01-AI078881\u2018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The advent of direct-acting antivirals (DAAs) has transformed the landscape of hepatitis C virus (HCV) management. We aimed to prospectively (real-time) evaluate the feasibility of using a response-guided therapy approach, based on mathematical modeling of early viral kinetics, to reduce the duration of DAAs therapy. Patients were treated with DAAs according to the physicians\u2019 preference. HCV was measured at baseline and at day 2 and weeks 1, 2 and 4 after treatment initiation. The primary endpoint was the proportion of patients with sustained-virological response (SVR) at 12 and\/or 24\u00a0weeks post-treatment. Twenty-nine patients (mean age 54\u2009\u00b1\u200916, 44% females, 73% with HCV genotype 1), were enrolled and all completed therapy. Treatment duration was shortened in 11 of the 29 patients (38%). SVR was achieved in 28 of the 29 patients (97%). Relapse occurred post treatment in a single case of a non-cirrhotic male with genotype 3, who was treated with sofosbuvir\/velpatasvir for 6\u00a0weeks. Virus sequencing did not identify baseline or treatment emergent resistance associated substitutions. Real-time mathematical modeling of early HCV kinetics can be utilized for shortening DAAs duration in approximately 40% of patients without compromising treatment efficacy.<\/jats:p>\n                  <jats:p>Clinical trial registration: ClinicalTrials.gov Identifier: NCT03603327.<\/jats:p>","DOI":"10.1038\/s41598-020-74568-x","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T06:03:16Z","timestamp":1603173796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study"],"prefix":"10.1038","volume":"10","author":[{"given":"Ohad","family":"Etzion","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harel","family":"Dahari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Yardeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assaf","family":"Issachar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Nevo-Shor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Cohen-Naftaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaffa","family":"Ashur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Uprichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly Sneh","family":"Arbib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Munteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Cotler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naim","family":"Abufreha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayelet","family":"Keren-Naus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonat","family":"Shemer-Avni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orna","family":"Mor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanah","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Novack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Shlomai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,20]]},"reference":[{"key":"74568_CR1","doi-asserted-by":"crossref","unstructured":"Polaris Observatory, H.C.V.C. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol. Hepatol.2, 161\u2013176 (2017).","DOI":"10.1016\/S2468-1253(16)30181-9"},{"key":"74568_CR2","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1093\/cid\/ciy585","volume":"67","author":"Panel, A.-I.H.G","year":"2018","unstructured":"Panel, A.-I.H.G. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin. Infect. Dis. 67, 1477\u20131492 (2018).","journal-title":"Clin. Infect. Dis."},{"key":"74568_CR3","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/cid\/civ396","volume":"61","author":"B Simmons","year":"2015","unstructured":"Simmons, B., Saleem, J., Heath, K., Cooke, G. S. & Hill, A. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin. Infect. Dis. 61, 730\u2013740 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"74568_CR4","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld, J. J. et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N. Engl. J. Med. 373, 2599\u20132607 (2015).","journal-title":"N. Engl. J. Med."},{"key":"74568_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","volume":"67","author":"PY Kwo","year":"2017","unstructured":"Kwo, P. Y. et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1\u20136 without cirrhosis. J. Hepatol. 67, 263\u2013271 (2017).","journal-title":"J. Hepatol."},{"key":"74568_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","volume":"383","author":"E Lawitz","year":"2014","unstructured":"Lawitz, E. et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 383, 515\u2013523 (2014).","journal-title":"Lancet"},{"key":"74568_CR7","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0140-6736(14)61793-1","volume":"385","author":"M Sulkowski","year":"2015","unstructured":"Sulkowski, M. et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV\/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 385, 1087\u20131097 (2015).","journal-title":"Lancet"},{"key":"74568_CR8","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1056\/NEJMra1810477","volume":"380","author":"DL Thomas","year":"2019","unstructured":"Thomas, D. L. Global elimination of chronic hepatitis. N. Engl. J. Med. 380, 2041\u20132050 (2019).","journal-title":"N. Engl. J. Med."},{"key":"74568_CR9","doi-asserted-by":"publisher","first-page":"660","DOI":"10.7326\/M15-0674","volume":"162","author":"O Etzion","year":"2015","unstructured":"Etzion, O. & Ghany, M. G. A cure for the high cost of hepatitis C virus treatment. Ann. Intern. Med. 162, 660\u2013661 (2015).","journal-title":"Ann. Intern. Med."},{"key":"74568_CR10","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1053\/jhep.2003.50364","volume":"38","author":"GL Davis","year":"2003","unstructured":"Davis, G. L. et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38, 645\u2013652 (2003).","journal-title":"Hepatology"},{"key":"74568_CR11","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1053\/j.gastro.2008.04.015","volume":"135","author":"P Ferenci","year":"2008","unstructured":"Ferenci, P. et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 135, 451\u2013458 (2008).","journal-title":"Gastroenterology"},{"key":"74568_CR12","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.jhep.2016.02.022","volume":"64","author":"H Dahari","year":"2016","unstructured":"Dahari, H. et al. HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir. J. Hepatol. 64, 1232\u20131239 (2016).","journal-title":"J. Hepatol."},{"key":"74568_CR13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s11901-011-0101-7","volume":"10","author":"H Dahari","year":"2011","unstructured":"Dahari, H., Guedj, J., Perelson, A. S. & Layden, T. J. Hepatitis C viral kinetics in the era of direct acting antiviral agents and IL28B. Curr. Hepat. Rep. 10, 214\u2013227 (2011).","journal-title":"Curr. Hepat. Rep."},{"key":"74568_CR14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/liv.12692","volume":"35","author":"H Dahari","year":"2015","unstructured":"Dahari, H. et al. Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics. Liver Int. 35, 289\u2013294 (2015).","journal-title":"Liver Int."},{"key":"74568_CR15","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nature03153","volume":"432","author":"NM Dixit","year":"2004","unstructured":"Dixit, N. M., Layden-Almer, J. E., Layden, T. J. & Perelson, A. S. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432, 922\u2013924 (2004).","journal-title":"Nature"},{"key":"74568_CR16","doi-asserted-by":"publisher","first-page":"e0187409","DOI":"10.1371\/journal.pone.0187409","volume":"12","author":"L Canini","year":"2017","unstructured":"Canini, L. et al. HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients. PLoS ONE 12, e0187409 (2017).","journal-title":"PLoS ONE"},{"key":"74568_CR17","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/liv.14014","volume":"39","author":"M Gambato","year":"2019","unstructured":"Gambato, M. et al. Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis. Liver Int. 39, 826\u2013834 (2019).","journal-title":"Liver Int."},{"key":"74568_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1126\/science.282.5386.103","volume":"282","author":"AU Neumann","year":"1998","unstructured":"Neumann, A. U. et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282, 103\u2013107 (1998).","journal-title":"Science"},{"key":"74568_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3851\/IMP3123","volume":"22","author":"Y Gozlan","year":"2017","unstructured":"Gozlan, Y. et al. HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patients. Antivir. Ther. 22, 431\u2013441 (2017).","journal-title":"Antivir. Ther."},{"key":"74568_CR20","doi-asserted-by":"publisher","first-page":"858","DOI":"10.4254\/wjh.v8.i20.858","volume":"8","author":"Y Hasin","year":"2016","unstructured":"Hasin, Y. et al. Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: case report. World J. Hepatol. 8, 858\u2013862 (2016).","journal-title":"World J. Hepatol."},{"key":"74568_CR21","first-page":"013","volume":"1","author":"EG Meissner","year":"2014","unstructured":"Meissner, E. G. et al. Sustained virologic response for chronic Hepatitis C infection after 27 days of treatment with sofosbuvir and ribavirin. Open Forum Infect. Dis. 1, 013 (2014).","journal-title":"Open Forum Infect. Dis."},{"key":"74568_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/1120009X.2017.1376782","volume":"30","author":"R Zampino","year":"2018","unstructured":"Zampino, R., Vitrone, M., Parrella, A., Ragone, E. & Durante-Mangoni, E. Can we go for a shorter treatment course in chronic hepatitis C? More inspiring cases.  J. Chemother. 30, 129\u2013130 (2018).","journal-title":"J. Chemother."},{"key":"74568_CR23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.15403\/jgld-2153","volume":"29","author":"D Yardeni","year":"2020","unstructured":"Yardeni, D. et al. Sustained virological response following an 11-day course of direct acting antiviral therapy for hepatitis C infection. J. Gastrointestin Liver Dis. 29, 270 (2020).","journal-title":"J. Gastrointestin Liver Dis."},{"key":"74568_CR24","doi-asserted-by":"publisher","first-page":"899","DOI":"10.7326\/M15-0642","volume":"163","author":"A Kohli","year":"2015","unstructured":"Kohli, A. et al. Four-week direct-acting antiviral regimens in noncirrhotic patients with hepatitis C virus Genotype 1 infection: an open-label, nonrandomized trial.  Ann. Intern. Med. 163, 899\u2013907 (2015).","journal-title":"Ann. Intern. Med."},{"key":"74568_CR25","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/liv.13335","volume":"37","author":"MS Sulkowski","year":"2017","unstructured":"Sulkowski, M. S. et al. Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study). Liver Int. 37, 836\u2013842 (2017).","journal-title":"Liver Int."},{"issue":"7","key":"74568_CR26","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/infdis\/jiaa219","volume":"222","author":"S Dasgupta","year":"2020","unstructured":"Dasgupta, S. et al. Modeling-based response-guided therapy for chronic hepatitis C under glecaprevir\/pibrentasvir may identify patients for ultra-short treatment duration. J. Infect. Dis. 222(7), 1165\u20131169 (2020).","journal-title":"J. Infect. Dis."},{"key":"74568_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S2468-1253(16)30015-2","volume":"1","author":"G Lau","year":"2016","unstructured":"Lau, G. et al. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. Lancet Gastroenterol. Hepatol. 1, 97\u2013104 (2016).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"74568_CR28","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/14787210.2019.1676730","volume":"17","author":"F McPhee","year":"2019","unstructured":"McPhee, F. Developments in the treatment of HCV genotype 3 infection. Expert Rev. Anti. Infect. Ther. 17, 775\u2013785 (2019).","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"74568_CR29","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jhep.2016.04.006","volume":"65","author":"B Maasoumy","year":"2016","unstructured":"Maasoumy, B. et al. Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. J. Hepatol. 65, 473\u2013482 (2016).","journal-title":"J. Hepatol."},{"key":"74568_CR30","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1093\/cid\/civ170","volume":"60","author":"S Sidharthan","year":"2015","unstructured":"Sidharthan, S. et al. Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. Clin. Infect. Dis. 60, 1743\u20131751 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"74568_CR31","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jhep.2014.01.002","volume":"60","author":"J Vermehren","year":"2014","unstructured":"Vermehren, J. et al. Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. J. Hepatol. 60, 913\u2013919 (2014).","journal-title":"J. Hepatol."},{"key":"74568_CR32","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.antiviral.2017.06.019","volume":"144","author":"A Goyal","year":"2017","unstructured":"Goyal, A. et al. Modeling HCV cure after an ultra-short duration of therapy with direct acting agents. Antiviral Res. 144, 281\u2013285 (2017).","journal-title":"Antiviral Res."},{"key":"74568_CR33","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jhep.2016.05.028","volume":"65","author":"H Dahari","year":"2016","unstructured":"Dahari, H., Halfon, P. & Cotler, S. J. Resurrection of response-guided therapy for sofosbuvir combination therapies. J. Hepatol. 65, 462\u2013464 (2016).","journal-title":"J. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74568-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74568-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74568-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T16:57:10Z","timestamp":1670345830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74568-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,20]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["74568"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-74568-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,20]]},"assertion":[{"value":"2 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.E. has consulted for Gilead and Abbvie and received lecture fees from Gilead, Abbvie and MSD. H.D. had\u00a0consulted for CoCrystal Inc. None of the other authors has any financial interest or conflict of interest related to this research.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17820"}}